EUCTR2012-000123-41-DE进行中（未招募）不适用
Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •[1] Postmenopausal women = 45 years of age at the time of entry into the trial, whose last menstrual period occurred at least 2 years prior to entry into the trial, and are sufficiently mobile to complete study visits. Women < 55 years of age in whom a bilateral oophorectomy cannot clearly be documented must
- •have their postmenopausal status confirmed by a serum FSH level > 40 IU/L and serum estradiol level < 20 pg/mL or < 73 pmol/L.
- •[2] A minimum of 2 moderate (SQ2) or 1 severe (SQ3) vertebral fragility fractures, confirmed by the central reader.
- •[3] AP lumbar spine or total hip or femoral neck BMD = 1.5 SD below the average BMD for young healthy, non-Hispanic, Caucasian women (T-score = –1.5 SD). Absolute BMD values will be applied to determine patient eligibility.
- •[4] Without language barrier, cooperative, able to come to the clinic for all follow-up visits; has given informed consent before entering the study and after being informed of the medications and procedures to be used in this study.
- •[5] In the opinion of the investigator, is willing to be trained and to use the pen injector daily, is able to satisfactorily use a pen-type injection delivery system, or is willing to receive daily subcutaneous injections from a caregiver who has been trained to use the pen injector.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[6] Increased baseline risk of osteosarcoma. This includes patients with Paget’s disease of the bone, previous primary skeletal malignancy, or skeletal exposure to therapeutic irradiation. As elevation of serum alkaline phosphatase activity may indicate the presence of Paget’s disease, an unexplained elevation of this enzyme activity will also be exclusionary.
- •[7] History of unresolved skeletal diseases that affect bone metabolism, other than osteoporosis, including renal osteodystrophy, osteomalacia, hyperparathyroidism
- •(uncorrected), hypoparathyroidism, and intestinal
- •malabsorption.
- •[8] Abnormally elevated values of serum albumin-corrected calcium levels at baseline, defined as = 10.6 mg/dL (or = 2.65 mmol/L). In cases with borderline non-eligible values (= 10.6 and = 10.7 mg/dL), a re-test would be allowed during the screening period.
- •[9] Abnormally low values of serum albumin- corrected calcium levels at baseline, defined as < 8.0 mg/dL (or < 2.0 mmol/L). In cases with borderline non-eligible values (> 7.8 to < 8.0 mg/dL), a re-test would be allowed during the screening period to allow normalization with vitamin D and calcium supplements before the randomization visit.
- •[10] Abnormally elevated values of serum intact PTH(1-84) at baseline defined as > 72 pg/mL (or > 7.6 pmol/L).
- •[11] Severe vitamin D deficiency at baseline defined as 25-hydroxy-vitamin D levels < 9.2 ng/mL (or < 23 nmol/L). In cases with borderline non-eligible values (> 8.0 and < 9.2 ng/mL), a re-test would be allowed during the screening period to allow normalization with vitamin D supplement before the randomization visit.
- •[12] Abnormal thyroid function not corrected by therapy. Patients with subclinical hyperthyroidism or hypothyroidism, defined as abnormally low or high TSH values respectively, with normal fT4 values are eligible to participate in the study.
- •[13] History of malignant neoplasms in the 5 years prior to Visit 2, with the exception of superficial basal cell or squamous cell carcinomas of the skin that have been definitively treated. Patients with carcinoma in situ of the uterine cervix treated definitively more than 1 year prior to entry into the study may
- •be randomized. Patients with multiple myeloma or metastases to bone are excluded.
- •[14] Active liver disease or clinical jaundice. Significantly impaired hepatic function, defined as AST > 75 U/L or ALT > 75 U/L or GGT > 300 U/L.
- •[15] Significantly impaired renal function as defined by a calculated endogenous creatinine clearance (ClCr) < 30 mL/min using the following Cockcroft-Gault formula for ClCr.
- •[16] History of nephrolithiasis or urolithiasis within 1 year prior to Visit 2.
- •[17] Considered imminent candidates for kyphoplasty or vertebroplasty before Visit 2.
- •[18] Patients who have been treated with kyphoplasty or vertebroplasty at 3 or more levels before Visit 2, regardless of the time since the last procedure.
- •[19] Patients who have been treated with kyphoplasty or vertebroplasty within the last 6 months before Visit 2.
- •[20] Patients with history of osteonecrosis of the jaw or who are, according to the clinical judgment of the investigator, at high risk to develop osteonecrosis of the jaw, including poor oral hygiene, scheduled invasive dental procedures, high doses of bisphosphonates and/or chemotherapy to treat malignancy.
- •[21] Patients with history of atypical subtrochanteric or diaphyseal femoral fractures, according to the diagnostic criteria of the American Society
研究者
相似试验
进行中（未招募）
1 期
A study in postmenopausal women with severe osteoporosis to compare the effects of two osteoporosis drugs (Teriparatide and Risedronate) on fractures of the spineEUCTR2012-000123-41-ESilly S.A.1,340
进行中（未招募）
1 期
A study in postmenopausal women with severe osteoporosis to compare the effects of two osteoporosis drugs (Teriparatide and Risedronate) on fractures of the spinePostmenopausal women with established osteoporosis and at least two moderate or one severe prevalent fragility fracture.MedDRA version: 16.1Level: LLTClassification code 10031288Term: Osteoporosis with fractureSystem Organ Class: 100000004859EUCTR2012-000123-41-ATEli Lilly and Company Limited1,340
进行中（未招募）
1 期
A study in postmenopausal women with severe osteoporosis to compare the effects of two osteoporosis drugs (Teriparatide and Risedronate) on fractures of the spinePostmenopausal women with established osteoporosis and at least two moderate or one severe prevalent fragility fracture.MedDRA version: 15.0Level: LLTClassification code 10031288Term: Osteoporosis with fractureSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-000123-41-ITELI LILLY1,340
进行中（未招募）
1 期
A study in postmenopausal women with severe osteoporosis to compare the effects of two osteoporosis drugs (Teriparatide and Risedronate) on fractures of the spinePostmenopausal women with established osteoporosis and at least two moderate or one severe prevalent fragility fracture.MedDRA version: 16.0Level: LLTClassification code 10031288Term: Osteoporosis with fractureSystem Organ Class: 100000004859EUCTR2012-000123-41-HUEli Lilly and Company Limited1,340
进行中（未招募）
1 期
A study in postmenopausal women with severe osteoporosis to compare the effects of two osteoporosis drugs (Teriparatide and Risedronate) on fractures of the spinePostmenopausal women with established osteoporosis and at least two moderate or one severe prevalent fragility fracture.MedDRA version: 18.0Level: LLTClassification code 10031288Term: Osteoporosis with fractureSystem Organ Class: 100000004859EUCTR2012-000123-41-CZEli Lilly and Company Limited1,340